Rare Disease Discussions cover art

All Episodes

Rare Disease Discussions — 192 episodes

#
Title
1

Spinal Muscular Atrophy: The Changing Definition of Success. An Expert Panel on the Evolution of SMA Care.

2

Growth Hormone Deficiency: Causes, Early Detection, and Treatment (Robert Rapaport, MD)

3

Arginine Vasopressin Deficiency (AVP-D) Overview (Christopher Romero, MD)

4

Systemic Mastocytosis: Recognition, Diagnosis, and Clinical Management

5

Prader-Willi Syndrome: Clinical Features and Early Identification

6

Submission of New Drug Application: Rusfertide for Polycythemia Vera

7

Current Issues in Gene Therapies for Lysosomal Disorders

8

Theranostics and Lysosomal Disorders

9

Expanded Applications of AI in Lysosomal Disorders

10

Organoids and Lab-Grown Models in Lysosomal Disorders

11

Nanotechnology and Lysosomal Disorders

12

AI in Medicine: Transforming the Landscape of Tissue-Based Diagnostics

13

Chapter 8: Gene Therapy Discussion and Q&A

14

Chapter 7: Changes in Gene Therapy Programs to Lessons Learned from Recent Trials

15

Chapter 6: Understanding and Preparing Risk Factors Associated With AAV Gene Therapies

16

Chapter 5: Factors Impacting Safety and Efficacy of AAV Mediated Gene Therapies

17

Ch 4: Clinical Safety and Efficacy Observed in AAV Mediated Gene Therapy Programs in DMD, SMA, XLMTM

18

Ch 3: Mitigation Strategies to Address the Challenges in the Development of Gene Therapy Programs

19

Chapter 2: AAV Mediated Gene Therapies

20

Chapter 1: Introduction to Gene Directed Therapies

21

Chapter 8: Gene Therapy Discussion and Q&A

22

Chapter 7: Ongoing Gene Therapies in Lysosomal Disorders

23

Chapter 6: Gene Replacement Therapy in Lysosomal Disorders

24

Chapter 5: Current Treatment Landscape and Limitations

25

Chapter 4: Lessons Learnt from Gene Therapy Trials

26

Chapter 3: Immune Responses and Other Safety Concerns Related to Gene Therapies

27

Chapter 2: Vectors, Different Strategies, Modes of Administration, and Targets

28

Chapter 1: Lysosomal Disorders and the Potential for Gene Therapies

29

Catching the Clues, Changing the Course of Lysosomal Storage Disorders

30

Consider Rare: Suspecting and Diagnosing CIDP

31

Lysosomal Disorders and the Brain

32

Case Studies in Diagnosing and Managing FOP

33

Immune Thrombocytopenia (ITP) Research Highlights: ISTH 2025

34

Immune Thrombotic Thrombocytopenic Purpura (iTTP) Research Highlights: ISTH 2025

35

Hemophilia Research Highlights: ISTH 2025

36

Myasthenia Gravis Clinical Research Highlights: AAN 2025

37

Mastocytosis Control Test: Implications for Physicians

38

Skeletal Involvement in Lysosomal Disorders

39

Fabry Disease Research Highlights

40

Consider Rare: Suspecting and Diagnosing Fibrodysplasia Ossificans Progressiva (FOP)

41

Progressive Familial Intrahepatic Cholestasis (PFIC): Diagnosing, Treating, Monitoring

42

Transforming Clinical Outcomes With Early Treatment of Lysosomal Disorders

43

PAH Research Highlights: CHEST 2024

44

Consider Rare: Suspecting and Diagnosing Hereditary Angioedema (HAE)

45

Improving Health Equity in Hereditary Angioedema (HAE): A Panel Discussion

46

Optimizing Therapeutic Proteins Through PEGylation: Key Parameters and Impacts

47

Hematologic Malignancies and Clinical Trial Participations: A Shared Decision-Making Approach

48

FcRn and Myasthenia Gravis

49

FcRn and Myasthenia Gravis: Pathophysiology

50

FCRn and Myasthenia Gravis: Treatment Options

51

Cushing’s Syndrome Treatment Research Highlights: ENDO 2024Continuing Education

52

CTCL: Shortening the Diagnostic Journey and Starting Treatment Early

53

CTCL: The Role of Dermatologists in Diagnosing and Caring for Patients

54

Myasthenia Gravis Research Highlights: AAN 2024

55

Fabry Disease From a Patient’s Perspective, Featuring Maya Kineen

56

Signs and Symptoms of Fabry Disease, Featuring Nicola Longo, MD

57

Fabry Disease Overview, Featuring William Burns, MD

58

Kidney Involvement in Lysosomal Disorders

59

HAE Treatment Advances: Highlights from ACAAI

60

Hereditary Angioedema: Current Treatment Options

61

Assessing, Monitoring, and Managing Respiratory Involvement in Lysosomal Disorders

62

Hereditary Angioedema: Current and Future Treatment Options

63

Alpha-Mannosidosis From a Mom’s Perspective, Featuring Rhonda Skipper

64

Diagnosing and Managing Alpha-Mannosidosis, Featuring Markey McNutt, MD, PhD

65

Signs and Symptoms of Alpha-Mannosidosis, Featuring Reid Sutton, MD

66

Alpha-Mannosidosis Overview, Featuring Laura Buch, MSPAS, PA-C

67

Myasthenia Gravis and the Complement System: Treatment Options

68

Myasthenia Gravis and the Complement System: Pathophysiology

69

Myasthenia Gravis and the Complement System

70

New Guidance To Treat Tumor-induced Osteomalacia (TIO)

71

New Guidance To Diagnose Tumor-induced Osteomalacia (TIO)

72

New Guidance To Diagnose and Treat Tumor-induced Osteomalacia (TIO)

73

Cushing's Disease Research Highlights: ENDO 2023

74

CME: Managing Cardiomyopathies in Lysosomal Disorders

75

Acromegaly Research Highlights: ENDO 2023

76

Thyroid Eye Disease: Overview, Diagnosis, and Treatment Options

77

Myasthenia Gravis Research Highlights: AAN 2023

78

Building and Maintaining a Multidisciplinary Team for Lysosomal Disorders

79

Myasthenia Gravis and the Need for Targeted Therapies

80

wAIHA Treatment-Options – Current and in Development (Chapter 3)

81

wAIHA Complications (Chapter 2)

82

wAIHA Pathophysiology and Diagnosis (Chapter 1)

83

Warm Autoimmune Hemolytic Anemia (wAIHA) - Full Program

84

CME: Fabry Disease Research Highlights

85

Gene Therapy to Treat Duchenne Muscular Dystrophy – Preliminary Clinical Trial Results

86

Growth Hormone Deficiency Research Highlights

87

Zero Relapses in Patients with NMOSD Given Ravulizumab

88

Hemophilia A Drug Given Priority Review Status

89

A Brief History of Newborn Screening

90

UT Southwestern Medical Center: a NORD Center of Excellence

91

Safety and Efficacy of PLN-74809 to Treat Idiopathic Pulmonary Fibrosis

92

New Report Estimates the Number of Rare Diseases is More Than 10,000

93

CME: Cushing’s Disease / Cushing’s Syndrome - Research Highlights

94

Positive Updated Results from MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma

95

CME: Pulmonary Arterial Hypertension (PAH) Research Highlights

96

Dr. Farber: The Impact of COVID-19 in the Diagnosis of Pulmonary Arterial Hypertension (PAH)

97

CME: The Immune System and Lysosomal Diseases

98

Growth Hormone Deficiency Research Highlights

99

PIK3CA-Related Overgrowth Syndrome (PROS)

100

Zero Relapses in Patients With NMOSD Given Ravulizumab

101

UT Southwestern Medical Center: a NORD Center of Excellence

102

Advances in Gene Therapy for Lysosomal Diseases

103

Advances in Gene Therapy for Lysosomal Diseases

104

Updates in Medical Management of Cushing’s Syndrome

105

Diagnosis and Comorbidities in Cushing’s Disease: New Consensus Summary Into Your Practice

106

Current and Emerging ERTs/SRTs

107

What is Dravet Syndrome?

108

What Is a Patient-Focused Drug Development (PFDD) Meeting?

109

Data From SHINE Study Shows Significant Breakthrough for Patients with Mantle Cell Lymphoma

110

What Is ENPP1 Deficiency?

111

PNH: Real-World Experience

112

Rare Diseases Cost Ten Times More Than Common Diseases

113

CME Webinar: Biomarkers in Lysosomal Storage Disorders

114

Hereditary Angioedema (HAE) Research Highlights: 2022 AAAAI Annual Meeting

115

An Interview With Dr. Raymond Wang About Mucopolysaccharidosis Type I (MPS I)

116

Positive Data from Regenxbio’s Gene Therapy Trials for MPS I and MPS II

117

What is Dystrophic Epidermolysis Bullosa?

118

The NORD Rare Disease Centers of Excellence

119

Data from Phase 3 Gene Therapy Trial in Hemophilia B Patients Very Encouraging

120

What Is Rett Syndrome?

121

Gene Therapy (RGX-111) to Treat Mucopolysaccharidosis Type I (MPS I)

122

Treatment Options for Myasthenia Gravis

123

Galactosemia Roundtable Discussion Overview

124

MPS II Research Highlights: WORLDSymposium 2022

125

Gaucher Disease Research Highlights: WORLDSymposium 2022

126

AADC Deficiency: Panel Discussion Overview

127

Paroxysmal Nocturnal Hemoglobinuria (PNH) Highlights from ASH 2021

128

Subasumstat + Rituximab Shown to Be Tolerable in Subsets of non-Hodgkin Lymphoma Patients

129

Dr Jerry Vockley Discusses Latest Phase 2 Data Assessing SYNB1618 To Treat Phenylketonuria (PKU)

130

Newborn Screening: Hemoglobinopathies and Newer Disorders on the RUSP

131

Newborn Screening: Metabolic Conditions

132

Newborn Screening: Talking to Parents

133

Newborn Screening: From RUSP to Reality

134

Pyruvate Kinase (PK) Deficiency Highlights from ASH 2021

135

Treatment Landscape for Relapsed and Refractory Multiple Myeloma

136

Teclistamab Monotherapy for Relapsed/Refractory Multiple Myeloma Patients

137

Lysosomal Storage Diseases: Central Symptoms and Comorbidities

138

Hereditary Angioedema (HAE) Highlights from ACAAI 2021 Annual Meeting

139

Positive Long-Term Data of Ibrutinib + Venetoclax as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL)

140

Positive Safety and Efficacy Results in Rett Syndrome Study

141

Safety of the Bispecific Antibody, REGN5458, in Multiple Myeloma Patients

142

Sustained uMRD Demonstrated in Elderly CLL Patients Receiving Ibrutinib plus Venetoclax

143

Dr Anne Pariser Provides an Overview of NIH’s Office of Rare Diseases Research

144

New and Emerging Phenotypes in Lysosomal Storage Disorders

145

Retinoid Therapy for Congenital Ichthyosis Shows Promise

146

Overview of Congenital Ichthyosis

147

Milademetan Shows Promise as Treatment for Multiple Cancer Types

148

Overview of Juvenile Idiopathic Arthritis (JIA)

149

New Insights into Lysosomal Storage Diseases’ Pathophysiology is Changing Treatment

150

Overview of Sarcomas

151

Current Treatment Options for Bone and Soft Tissue Sarcomas

152

How the MMRF Is Advancing Multiple Myeloma Research

153

What is Krabbe Disease?

154

Gene Therapy Clinical Trial for Krabbe Disease is Recruiting Patients

155

TCGT: Overview, Symptoms, and the Need for a Multidisciplinary Approach

156

Acromegaly Highlights from ENDO 2021

157

Current and Emerging Treatments for Lysosomal Storage Diseases

158

Fabry Disease Research Highlights 2021

159

Prader-Willi Syndrome Overview

160

Investigational Drug Provides Improved Quality of Life for PNH Patients

161

What is Paroxysmal Nocturnal Hemoglobinuria?

162

Follicular Lymphoma and Marginal Zone Lymphoma

163

Phase 2 UNITY-NHL Study Regarding Umbralisib

164

FDA Approves Umbralisib for Marginal Zone Lymphoma, Follicular Lymphoma

165

Prader-Willi Syndrome: Overview and Potential Treatment

166

Rare Disease Clinical Trials: Study Designs and Common Concerns

167

Gaucher Disease Research Highlights

168

Eye on Neuromyelitis Optica Spectrum Disorder (NMOSD)

169

PAH Highlights from CHEST 2020

170

Fabry Disease Research Highlights

171

Gaucher Disease Research Highlights

172

Mucopolysaccharidoses (MPSs) Research Highlights

173

When to Suspect ATTR Amyloidosis

174

Diagnosing ATTR Amyloidosis

175

Spinal Muscular Atrophy and Genetic Counseling

176

Spinal Muscular Atrophy and Newborn Screening

177

Treating Spinal Muscular Atrophy

178

Diagnosing Spinal Muscular Atrophy

179

NETS Research Highlights

180

Rolling Submission for Cilta-cel to Treat Relapsed/Refractory Multiple Myeloma

181

Clinical Data Shows Promise for SCID Treatment

182

Gene Therapy Showing Promise in Treating XLRP

183

Narcolepsy Highlights from AAN 2020

184

NMOSD Highlights from AAN 2020

185

Newborn Screening and MPS I

186

Mucopolysaccharidosis I (MPS I) and Genetic Counseling

187

Treating Mucopolysaccharidosis I (MPS I)

188

Diagnosing Mucopolysaccharidosis I (MPS I)

189

Mucopolysaccharidosis I (MPS I) and Genetic Counseling

190

Tumor-induced Osteomalacia (TIO)

191

New Study to Treat Propionic Acidemia and Methylmalonic Acidemia

192

CheckRare: Diagnosing Gaucher Disease Before ERT